Literature DB >> 26950685

Beta-haemolytic streptococcal endocarditis: clinical presentation, management and outcomes.

Abdelghani El Rafei1, Daniel C DeSimone1, Christopher V DeSimone2, Brian D Lahr3, James M Steckelberg1, Muhammad R Sohail1,2, Walter R Wilson1, Larry M Baddour1,2.   

Abstract

BACKGROUND: Beta-haemolytic streptococcal (BHS) endocarditis is rare, but well-recognised for its high morbidity and mortality. This study sought to further characterise clinical features, management and outcomes of BHS endocarditis.
METHODS: Retrospective review of all adultpatients (≥ 18 years old) with BHS endocarditis treated at the Mayo Clinic from 1 January 2000 to 31 December 2014.
RESULTS: Forty-nine cases of BHS endocarditis were identified with a mean (± SD) age of 64 (± 14.9) years and 65% were males. The infection was community acquired in 92% of the cases, with a median (IQR) time to diagnosis from symptom onset of 6 days (5-10). Associated conditions included the presence of a prosthetic valve (41%), malignancy (33%) and diabetes mellitus (DM) (31%). Median (IQR) vegetation size was 12 mm (9-17 mm). In a univariate analysis patients with DM had larger vegetations, median (IQR) = 17 mm (10.5-26 mm) compared to non-diabetic patients, median (IQR) = 11 mm (8-15 mm) (p = 0.01). Septic brain emboli occurred in 43% of cases. Eighteen patients (37%) underwent early (within 30 days) surgery. All-cause 1 month and 6 month mortality rates were 25% and 31%, respectively.
CONCLUSION: BHS endocarditis has an acute onset and is complicated by relatively large vegetations with a high rate of systemic embolisation. DM was the second most common associated medical condition and patients with DM had larger vegetations. Despite medical and surgical advances, mortality due to BHS endocarditis remains high, particularly within 30 days of diagnosis.

Entities:  

Keywords:  Infective endocarditis; beta-haemolytic streptococci; diabetes mellitus; mortality; surgery

Mesh:

Substances:

Year:  2016        PMID: 26950685     DOI: 10.3109/23744235.2015.1129672

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  5 in total

1.  Infective endocarditis due to Streptococcus dysgalactiae: clinical presentation and microbiological features.

Authors:  Anna Bläckberg; Bo Nilson; Volkan Özenci; Lars Olaison; Magnus Rasmussen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-08       Impact factor: 3.267

2.  Virulence of beta-hemolytic streptococci in infective endocarditis.

Authors:  Yvon Ruch; Yves Hansmann; Philippe Riegel; Nicolas Lefebvre; Jean-Philippe Mazzucotelli; Nawal Douiri; Aurélie Martin; Xavier Argemi
Journal:  Infection       Date:  2019-09-13       Impact factor: 3.553

3.  A comparison of different antibiotic regimens for the treatment of infective endocarditis.

Authors:  Arturo J Martí-Carvajal; Mark Dayer; Lucieni O Conterno; Alejandro G Gonzalez Garay; Cristina Elena Martí-Amarista
Journal:  Cochrane Database Syst Rev       Date:  2020-05-14

4.  Beta-Hemolytic Streptococcal Infective Endocarditis: Characteristics and Outcomes From a Large, Multinational Cohort.

Authors:  Núria Fernández Hidalgo; Amal A Gharamti; María Luisa Aznar; Benito Almirante; Mohamad Yasmin; Claudio Querido Fortes; Patrick Plesiat; Thanh Doco-Lecompte; Hussein Rizk; Dannah Wray; Cristiane Lamas; Emanuele Durante-Mangoni; Pierre Tattevin; Ulrika Snygg-Martin; Margaret M Hannan; Vivian H Chu; Zeina A Kanafani
Journal:  Open Forum Infect Dis       Date:  2020-04-10       Impact factor: 3.835

5.  Streptococcus pyogenes Infective Endocarditis-Association With Injection Drug Use: Case Series and Review of the Literature.

Authors:  Melanie T Rebechi; Emily L Heil; Paul M Luethy; Sarah A Schmalzle
Journal:  Open Forum Infect Dis       Date:  2021-05-11       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.